A Study to Evaluate SAGE-217 in Participants With Essential Tremor
Status:
Completed
Trial end date:
2017-12-05
Target enrollment:
Participant gender:
Summary
This study is a three-part, multicenter, Phase 2a study to evaluate the efficacy, safety,
tolerability, and pharmacokinetics of SAGE-217 in adult participants with essential tremor.